Working… Menu

Early (4 Days) Versus Standard Drainage of the Abdominal Cavity After Pancreaticoduodenectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01368094
Recruitment Status : Completed
First Posted : June 7, 2011
Last Update Posted : May 3, 2016
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:

Around two thousand pancreaticoduodenectomy (PD) are performed each year in France. This intervention is associated with a high rate of postoperative complications including:

  • pancreatic fistulas (PF);
  • surgical site infections (intra-abdominal abscess, wound infection);
  • delayed gastric emptying (gastroparesis);
  • and hemorrhage.

The incidence of SSI (superficial and deep) is about 35% and seems influenced by the prolonged intra-abdominal drainage. For several years, there has been a global trend to reduce the use of abdominal drainage after abdominal surgery. Several randomized clinical trials have shown that prophylactic drainage does not decrease the incidence of postoperative complications during elective hepatectomy, colectomy, and cholecystectomy and could increase the number of SSI. However, the role of prophylactic drainage after PD is so far unclear.

The aim of this prospective randomized multicenter study is to evaluate the influence of early (4 days) versus standard (10 to 15 days, depending on the staff clinical practice) drainage removal of the abdominal cavity after PD, on the rate of SSI.

Materials and Methods: The technique of PD is left at the discretion of the operator as well as the prescription of analogues of somatostatin. Drainage of the abdominal cavity is made of one or two round silicone close suction drains or open multichannel silicone drains placed in the vicinity of the pancreatic and biliary anastomosis. Shall be excluded patients operated on for chronic pancreatitis and patients who underwent preoperative radiotherapy. The 3rd postoperative day, a fistula is sought clinically, biologically and on CT-scanner images. In case of pancreatic fistula, the patient is excluded from randomization and drainage of the abdominal cavity is left in place depending on the different teams' practice. Patients without fistula are randomized to either drainage removal 4 days after surgery (D4) or standard drainage.

Condition or disease Intervention/treatment Phase
Pancreatic Disease Pancreatic Neoplasms Procedure: Drain removal at D4 Procedure: Standard drain removal Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 141 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Early (4 Days) Versus Standard Drainage Removal of the Abdominal Cavity After Pancreaticoduodenectomy- - A Randomized Multicenter Study
Study Start Date : June 2011
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Standard drainage Procedure: Standard drain removal
If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.

Experimental: Short drainage Procedure: Drain removal at D4
If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.

Primary Outcome Measures :
  1. Surgical Site Infection at D30 [ Time Frame: 30 days after surgical intervention ]

    The outcome measure is the occurrence of surgical site infection (SSI) at D30, as defined by:

    • surface SSI (wound abscess): infection of the skin, subcutaneous tissue or muscle, above the fascia, located at a surgical incision.
    • deep SSI (intra-abdominal abscess) infection in operated tissues or in site of intervention (under the fascia).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pancreatic tumor regardless of its nature: All patients requiring PD (following thesaurus or multidisciplinary team council recommendation) for this indication will be included.
  • Ability to participate in a clinical research protocol.
  • Given informed consent.

Exclusion Criteria:

  • History of pancreatic surgery or biliary diversion and / or digestive
  • Patient taken in charge for chronic pancreatitis without tumor
  • History of supramesocolic radiotherapy
  • Sick supported emergency
  • Physical or mental condition does not allow participation in the study
  • Contra-indication to surgery
  • ASA classification (American Society of Anesthesiologists) IV-V or life expectancy <48
  • Pregnancy or breastfeeding
  • Patient under guardianship or private patient of liberty by a judicial or administrative decision
  • Age under 18yo

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01368094

Layout table for location information
CHU Amiens
Amiens, Picardie, France, 80000
Centre Hospitalier de Beauvais
Beauvais, France, 60000
Centre Hospitalier Saint-Martin
Caen, France, 14050
Centre Hospitalier Régional Universitaire Claude Huriez
Lille, France, 59037
Centre Hospitalier Charles Nicolle
Rouen, France, 76 031
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Layout table for investigator information
Principal Investigator: Jean-Marc REGIMBEAU, Pr Centre Hospitalier Régional Universitaire d'Amiens
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens Identifier: NCT01368094    
Other Study ID Numbers: PHRCIR10-PR-REGIMBEAU
2010-A01347-32 ( Other Identifier: ID-RCB )
First Posted: June 7, 2011    Key Record Dates
Last Update Posted: May 3, 2016
Last Verified: May 2016
Keywords provided by Centre Hospitalier Universitaire, Amiens:
Surgical site infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Pancreatic Diseases
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Endocrine System Diseases